Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Thu, 02.03.2023
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, March 2, 2023
Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
MorphoSys AG (FSE: MOR; NASDAQ: MOR) (the “Company”) today announces [ … ]
Thu, 02.03.2023
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, March 2, 2023
Ad hoc: MorphoSys Stops Work and Operations on Pre-Clinical Research Programs and Reduces Workforce at its Germany Headquarters
MorphoSys AG (FSE: MOR; NASDAQ: MOR) (the “Company”) today announces [ … ]
Mon, 09.01.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 9, 2023
MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MANIFEST-2 study – a global, randomized, double-blind clinical trial exploring pelabresib, an inves [ … ]
Thu, 05.01.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 5, 2023
MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
Preliminary 2022 Monjuvi U.S. net product sales of US$ 89.4 million (€ 84.9 million)
Anticipated 2023 Monjuvi U.S. net product sales in the range of US$ 8 [ … ]
Thu, 05.01.2023
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, January 5, 2023
Ad hoc: MorphoSys AG Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability
Preliminary 2022 Monjuvi U.S. net product sales of U [ … ]
Tue, 20.12.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 20, 2022
Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Sung Lee, the company’s Chief Financial Officer (CFO) and Management Board member, has decided to leave MorphoSys to move back to California for personal reasons. [ … ]
Tue, 20.12.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 20, 2022
Chief Financial Officer Sung Lee to Leave MorphoSys in March 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that Sung Lee, the company’s Chief Financial Officer (CFO) and Management Board member, has decided to leave MorphoSys to move back to California for personal reasons. [ … ]
Sun, 11.12.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 11, 2022
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
Data from the MANIFEST trial show durable improvements in both spleen volume and symptom score beyond 24 weeks with pelabresib in combination [ … ]
Sun, 11.12.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, December 11, 2022
MorphoSys Presents New Longer-term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity, at ASH 2022
Data from the MANIFEST trial show durable improvements in both spleen volume and symptom score beyond 24 weeks with pelabresib in combination [ … ]
Sat, 10.12.2022
MorphoSys AG
Media Release
PLANEGG/MUNICH, Germany, December 10, 2022
MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
Final analysis from the Phase 1b firstMIND trial shows no new safety signals and provides additional information on progression-free survival at 24 months for pat [ … ]